Pharmaceuticals
Yuyu Pharma Explores Animal Health as a New Pathway for Human Drug Innovation
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities ac...
2026-10-29 21:00
3539
SGH's AI tool wins international award for improving antibiotic use
SINGAPORE, Oct. 29, 2026 /PRNewswire/ -- Singapore General Hospital (SGH) has won the Silver Award in the Dr Prathap C Reddy Excellence Award for Clinical Quality and Patient Safety at the International Hospital Federation (IHF) Awards 2026, for its Augmented Intelligence in Infectious Diseases (...
2026-10-29 14:00
3937
Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease
TOKYO, Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NT...
2026-10-29 10:00
3439
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no platea...
2026-10-29 07:40
3843
Median PFS Approaches 14 Months! 3SBio's PD-1/VEGF Bispecific Antibody Posts Impressive Data at ESMO 2026
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- At the 2026 European Society for Medical Oncology (ESMO) Congress, 3SBio presented long-term follow-up results from a Chinese Phase II clinical study of SSGJ-707 combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (N...
2026-10-28 20:56
3563
Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad. The center was unveiled at the inaugural Jiahui International Cell The...
2026-10-28 14:41
2395
The Jumbophage Cocktail_Fighting Superbugs and Shrimp Disease
BANGKOK, Oct. 28, 2026 /PRNewswire/ -- What if a weapon against some of the world's most stubborn bacteria were hiding in the soil beneath our feet? Could these microscopic hunters help us confront antibiotic-resistant "superbugs" and bacterial diseases devastating shrimp? The answer may lie in u...
2026-10-28 14:24
3388
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment
Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's pharmaceuti...
2026-10-28 11:32
3845
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...
2026-10-28 08:00
4300
Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services
GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...
2026-10-28 08:00
5050
Piramal Pharma Limited Announces Results for Q2 and H1 FY27
MUMBAI, India, Oct. 27, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Cons...
2026-10-28 03:28
7132
Fios Genomics bioinformatics team and services move to Excelra
Edinburgh-based team joins Excelra's scientific consulting group, strengthening
its omics analytics expertise and presence in the UK and Europe
EDINBURGH, Scotland and HYDERABAD, India, Oct. 27, 2026 /PRNewswire/ --
Excelra
2026-10-27 23:00
2820
Registrational Phase III CLARIFY trial: Target number of participants achieved
SYDNEY, Oct. 27, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registration...
2026-10-27 21:02
3088
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
* This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. * The Phase III OptiTROP-Lung06 study supporting this application showed that sac-TMT plus p...
2026-10-27 19:10
3810
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was...
2026-10-27 18:04
3833
IX at IPVS 2026: Listening to Global Voices, Partnering to Advance HPV Prevention
ATHENS, Greece, Oct. 27, 2026 /PRNewswire/ -- Xiamen Innovax Biotech Co., Ltd. (IX) participated in the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), held in Athens, Greece, from October 22 to 25, joining global experts and partners to exchange scientific insight...
2026-10-27 14:35
2380
MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation
* Automated system enables rapid, reproducible formulation screening with minimal sample consumption * Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., ...
2026-10-26 22:00
2752
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 gener...
2026-10-26 21:00
5087
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading programs in this class globally - First patient dosing marks a key milestone for TJ Biopharma's next-generation innovation pipeline HANGZHOU, China, Oct....
2026-10-26 20:00
3638
Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology
CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...
2026-10-26 18:33
3815
Week's Top Stories
Most Reposted
/C O R R E C T I O N - Autodesk, Inc./
[Picked up by 1321 media titles]
2026-10-29 01:23
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1167 media titles]
2026-11-02 20:00Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software
[Picked up by 1148 media titles]
2026-10-28 20:30Piramal Pharma Limited Announces Results for Q2 and H1 FY27
[Picked up by 1084 media titles]
2026-10-28 03:28Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59051
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54027
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52116
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21563
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
16868